Immunovant (NASDAQ:IMVT) Receives Buy Rating from HC Wainwright

On March 22, 2025, HC Wainwright reiterated their buy rating for shares of Immunovant (NASDAQ:IMVT). They have set a target price of $51.00 for the stock, indicating continued confidence in the company’s potential.

Several other analysts have also recently offered their insights on Immunovant. For instance, Bank of America lowered their price target from $48.00 to $45.00 but maintained a ‘buy’ rating for the firm in their report dated January 15th. Cantor Fitzgerald upgraded Immunovant to a ‘strong-buy’ rating on March 4th. In another analysis, Wells Fargo & Company decreased their target price from $47.00 to $45.00, classifying the stock as ‘overweight’ in their note from December 19th. Guggenheim also reaffirmed a ‘buy’ rating on March 10th. However, during this period, Wolfe Research downgraded Immunovant from an ‘outperform’ rating to a ‘peer perform’ rating in their report dated January 3rd. Overall, out of the analysts closely following the stock, one has assigned a hold rating, nine have issued buy ratings, and one has designated a strong buy rating. As per the consensus data from MarketBeat.com, Immunovant holds an average rating of ‘Buy’ with a consensus price target of $41.70.

Performance Metrics of Immunovant

On the trading session following the announcement, Immunovant shares opened at $19.64. Over the past year, the stock reached a low of $17.01 and a high of $34.47. Currently, the company has a market capitalization of approximately $3.34 billion, with a negative price-to-earnings ratio of -7.50 and a beta of 0.68. The stock's 50-day moving average stands at $20.86, while the 200-day moving average is at $25.71.

Immunovant recently released its quarterly earnings results on February 10th. For the quarter, the company reported earnings per share of ($0.76), which fell short of analysts’ expectations of ($0.68) by $0.08. Forecasts suggest that Immunovant is likely to post an earnings per share of -2.69 for the current year.

Insider Activity

In insider trading news, Director Andrew J. Fromkin sold 8,000 shares on March 7th at an average price of $19.60, generating a transaction worth $156,800. Post-sale, he retains 91,913 shares, valued at around $1.80 million, representing a decrease of 8.01% in his ownership. Additionally, CEO Peter Salzmann sold 5,105 shares on January 8th at an average price of $24.10, amounting to a total of $123,030.50. Consequently, he now owns 972,992 shares worth approximately $23.45 million, marking a decrease of 0.52% in his holdings. Over the last quarter, insiders have sold a total of 35,510 shares, with company insiders holding about 5.90% of the stock.

Institutional Investor Activity

Institutional investment in Immunovant has also seen recent changes, with GF Fund Management CO. LTD. acquiring a new stake valued at $76,000 in the last quarter. Two Seas Capital LP notably increased their stake by 123.4% during the same period and now owns 1,511,614 shares valued at $37.44 million. Other investors such as Vestal Point Capital LP and Twinbeech Capital LP also made new acquisitions, bringing significant capital into Immunovant. After these transactions, institutional investors hold approximately 47.08% of Immunovant’s shares.

About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company that specializes in developing monoclonal antibodies aimed at treating autoimmune diseases. Their key product is batoclimab, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor, which is in development for conditions such as myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves' disease, and warm autoimmune hemolytic anemia.

Immunovant, Stocks, Analysis